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Background: There was concern that failure to screen women aged 20–24 years would increase the number of cancers or
advanced cancers in women aged 20–29 years. We describe the characteristics of women diagnosed with cervical cancer in
England aged 20–29 years and examine the association between the period of diagnosis, screening history and FIGO stage.
Methods: We used data on 1800 women diagnosed with cervical cancer between April 2007 and March 2012 at age 20–29 from
the National Audit of Invasive Cervical Cancers.
Results: The majority of cancers (995, or 62% of those with known stage) were stage 1A. Cancer at age 20–24 years was rare
(12% of those aged 20–29 years), when compared with age 25 (24%) and age 26–29 years (63%); however, cancers in women aged
20–24 years tended to be more advanced and were more often of a rare histological type. For 59% of women under age 30, the
cervical cancer was screen detected, most of them (61%) as a result of their first screening test. A three-fold increase in the number
of cancers diagnosed at age 25 years was seen since the start of the study period.
Conclusion: Cervical cancer at age 20–24 years is rare. Most cancers in women under age 30 years are screen detected as
microinvasive cancer.
With the introduction of the cervical screening programme in 1988
it was hoped that cervical cancer could be almost eliminated,
particularly in young women. In fact, the introduction of screening
has not only prevented cancers but has also led to those cancers in
screened women that are not prevented being diagnosed at much
earlier stages. Because the lead time between the onset of early-
stage occult cervical cancer and the development of symptoms can
be considerable, screening has led to a shift in the peak incidence
of cervical cancer (among women eligible for screening) from age
35–49 years in 1993–1995 to age 25–34 years in 2007–2009
(Cancer Research UK, 2010). In addition, cancer rates have steadily
been increasing over the past 20 years in young women (Foley et al,
2011), possibly because of changes in the underlying rates of
sexually transmitted infections including human papilloma virus
(PHLS Communicable Disease Surveillance Centre, 2006a,b;
Sargent et al, 2008).
There is increasing evidence that cervical screening in women
aged 20–24 years is not as effective in preventing cervical cancer as
screening women aged 25þ years (Sasieni et al, 2003, 2009).
Therefore, in late 2003, a change in cervical screening policy was
announced whereby women in England would first be invited at
their 25th birthday instead of from age 20 years. There was concern
among some that the change in policy would lead to an increase
in cervical cancer and in particular to an increase in cancers
diagnosed at more advanced stages (Herbert et al, 2008;
Fiander, 2008).
The new policy was rolled out in 2004, but was not retrospective
in that women already invited for screening before age 25 years
would receive a second invitation 3 years later even if still under
age 25 years. In addition, it took B15 months to roll out the
change in policy nationally. It was only from mid 2009 that
substantial numbers of women would have received a first
*Correspondence: Dr A Castanon; E-mail: a.castanon@qmul.ac.uk
Received 12 April 2013; revised 4 June 2013; accepted 4 June 2013;
published online 2 July 2013
& 2013 Cancer Research UK. All rights reserved 0007 – 0920/13
FULL PAPER
Keywords: cervical cancer; screening; young women; screening history
British Journal of Cancer (2013) 109, 35–41 | doi: 10.1038/bjc.2013.322
www.bjcancer.com |DOI:10.1038/bjc.2013.322 35
screening invitation at age 25 years. Thus, to see the full impact of
the change to the screening policy, we will need to wait until the
cohort of women first invited for screening at age 25 years (those
born since 1984/1985) reach the age of 30 years.
At the May 2009 meeting of the Advisory Committee on
Cervical Screening (ACCS), the change in the screening policy was
re-examined, and recommendations were made to the National
Cancer Director and Ministers. Both in the meeting and in the
recommendations, an emphasis was placed on monitoring and
surveillance, so that important changes in the incidence and/or the
stage of cancer in women aged 20–29 years could be identified as
soon as possible (Department of Health, 2010).
Here we aim to describe the characteristics of women who
develop cervical cancer in their twenties in terms of stage at
diagnosis, histology, treatment and socioeconomic status, and to
examine changes in screening history by stage.
MATERIALS AND METHODS
Subjects. We used data on women in England diagnosed with
cervical cancer (ICD-10 C53) aged 20–29.99 years between April
2007 and March 2012 from the National Audit of Invasive Cervical
Cancers (October 2012 data set). The audit includes over 90% of
all cancers diagnosed nationally. The screening histories of these
women were abstracted from routinely recorded cervical cytology
records held on the National Cervical Screening Call/Recall
System, including all NHS and many private tests. Treatment
details, FIGO stage at diagnosis and histological type are recorded
as and when the data become available. As these data are collected
from multiple sources, they are not as complete or accurate as the
screening history data. Details of the audit have been published
previously (Sasieni et al, 2003, 2009).
Statistical methods. Descriptive statistics were examined to
compare the distributions of the International Federation of
Gynaecology and Obstetrics (FIGO) staging system at diagnosis,
histology, treatment, period of diagnosis, deprivation and screening
history. w2 tests were used to test for differences between the age
groups.
Deprivation was measured using the index of multiple
deprivation (IMD) (Department for Communities and Local
Government, 2011), a composite measure of seven domains of
deprivation, including income and employment. It is derived from
each woman’s postcode and divided into national deciles. We
divided the women into three groups based on their IMD: the three
most deprived deciles, the next three deciles and the four least
deprived deciles. In two regions, IMD was not recorded.
Consequently we included ‘unknown’ as a separate IMD category.
Similarly, when histology, treatment or stage was unknown, a
separate ‘unknown’ category was formed. These categories were
ignored when testing for differences between age groups.
Rates were calculated using the ONS mid-year population
estimates for the relevant years (Office for National Statistics,
2013).
Unfortunately, we are unable to ascertain if and when women
were invited for a cytology test. This means that we are unable to
distinguish women who attended as part of routine screening from
women who attended because of symptoms. However, it is
extremely unlikely that a woman could be diagnosed with cervical
cancer within 14 days of a routine screen. It typically takes 14 days
for a woman to receive the result of her screening test (and it used
to take considerably longer); we therefore assume that any woman
diagnosed within 14 days of a test was referred on the day the
cytology was taken and that the result of the cytology had no
influence on her pathway to diagnosis (Health and Social Care
Information Centre, 2012).
In addition, the change in policy (from first inviting women at
age 20 to age 25 years) occurred over a 15-month period, and
hence it is not possible to determine whether women born between
26 August 1984 and 3 November 1985 were invited for screening
from age 20 years or not. To assess the impact of the change in
policy, we have divided the data set into three time periods of 20
months each. The first period (‘mostly invited from 20’) includes
those diagnosed from April 2007 to November 2008; during this
period, all women diagnosed at age 25–29 years would have been
invited for screening at age 20 years. The middle period (‘mixed’)
runs from December 2008 to July 2010; in this period, some of
those women diagnosed aged 25 years were first invited at age 20
and some at 25 years. The final period (‘mostly invited from 25’)
runs from August 2010 to March 2012, when almost all women
diagnosed aged 25 years would have been first invited for screening
at age 25 years. Note that none of the women diagnosed aged
20–21 years in this study were invited for screening before
diagnosis, and all of those diagnosed at age 27–29 years should
have been invited at age 20 years.
Delays in the registration of newly diagnosed cancers in our
audit mean that the number of cases will be underreported,
particularly in the most recent period. To adjust for this we have
inflated the rates (but not the numbers) in the last period (August
2010 to March 2012). The inflation factor (13.9%) is the
proportion by which the number of cases aged 20–29 years
diagnosed between August 2008 and March 2010 increased
between the 2010 and the 2012 data sets. The inflation factor is
generous and there is evidence that reporting into the
audit is becoming timelier; over the period August 2009 to March
2011, the increase between the 2011 data set and the 2012 data set
was 8.7% compared with 11.1% for the corresponding periods a
year earlier.
We have classified the pathway to diagnosis for these women
according to their screening history as follows (full details can be
found in Appendix 1):
(1) Never screened or lapsed: women with no screening history
(more than 14 days before diagnosis) other than possibly a
single inadequate test; women (N¼ 23) whose last test resulted
in routine recall and was over 3.5 years before diagnosis (the
group labelled ‘lapsed’ in Appendix 1).
(2) Screen detected prevalent (on first test): women diagnosed
within 4 months of cytology indicating referral to colposcopy.
In addition, there should be no prior test resulting in routine
recall, and if the first screening test resulted in early recall, the
next test must be within 1 year.
(3) Screen detected incident: diagnosed between 2.75 and 3.5 years
after a negative test. The interval following an early recall test
(if any) must not exceed 1 year and they must have a cytology
test indicating referral to colposcopy within 4 months of
diagnosis.
(4) Screen detected lapsed: diagnosed 43.5 years after a negative
test. Same definition as (3) above, but the women have a
negative test 43.5 years before the abnormal test.
(5) Post abnormal: The interval following early recall tests (if any)
exceeds 1 year and/or they are diagnosed more than 4 months
after a cytology indicating referral to colposcopy or they have
no suspends but they have a history of low-grade cytology
resulting in early recall.
(6) Interval cancers: women diagnosed o2.75 years after a
cytology test resulting in routine recall. Also includes women
diagnosed between 2.75 and 3.5 years after a cytology test
resulting in routine recall, but with no other tests before
diagnosis, or women with their first early recall on the pathway
to diagnosis 2.75–3.5 years after a cytology test resulting in
routine recall, with no more than a year between an early recall
and the following test or diagnosis.
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RESULTS
The study includes a total of 1800 women diagnosed with cervical
cancer aged 20–29 years between April 2007 and March 2012. The
majority of cancers (63.2%) were diagnosed between the age of 26
and 29 years, with a further 24.4% diagnosed at age 25 years.
Cervical cancer is rare in women aged 20–24 years compared with
women aged 25–29 years, with only 12.4% (n¼ 223) of cancers
diagnosed in this age group, which is roughly equivalent to the
number of cancers diagnosed at age 26 years (n¼ 257).
Furthermore, half (n¼ 110) of all cancers diagnosed at age
20–24 years were diagnosed at age 24 years, 25% (n¼ 56) at age
23 years and 26% (n¼ 57) at age 20–22 years.
Table 1 shows the characteristics of these women by age at
diagnosis. Over 60% of cancers in this age group are diagnosed as
stage 1A and, across all stages, 69% are treated conservatively with
fertility-sparing treatment (the proportion increases to 94% among
those with stage 1A cancer and known treatment). Cancers in
women aged 20–24 years tend to be more advanced at diagnosis
than those in older women: a higher proportion of women under
age 25 years had stage 2 or worse cancer (20% vs 6%, Po0.001),
resulting in more women treated by chemotherapy and/or
radiotherapy±hysterectomy (37% vs 14%, Po0.001) and a smaller
proportion having fertility-sparing treatment (46% vs 72%,
Po0.001); a higher proportion were diagnosed with adenosqua-
mous carcinoma and other rarer histological types (10% vs 4%,
Po0.001). No differences in socioeconomic status were observed
Table 1. Characteristics of women diagnosed with cervical cancer aged 20–29 years
Age 20-24 Age 25 Age 26–29 All ages
N % N % N % N %
Stage
1A 77 40.7% 293 74.9% 625 60.4% 995 61.6%
1B 74 39.2% 83 21.2% 333 32.2% 490 30.3%
2þ 38 20.1% 15 3.8% 77 7.4% 130 8.0%
Unknown 34 — 49 — 102 — 185 —
Histology
Squamous 163 75.5% 352 82.8% 863 79.0% 1378 79.5%
Adenocarcinoma 32 14.8% 55 12.9% 186 17.0% 273 15.8%
Adenosquamous 9 4.2% 9 2.1% 28 2.6% 46 2.7%
Other 12 5.9% 9 2.1% 15 1.4% 36 2.1%
Unknown 7 — 15 — 45 — 67 —
Treatment
Cone biopsy or trachelectomy 71 45.8% 227 80.5% 560 69.1% 858 68.8%
Hysterectomy (simple or radical) 26 16.8% 26 9.2% 131 16.2% 183 14.7%
Chemotherapy and/or radiotherapy±hysterectomy 58 37.4% 29 10.3% 119 14.7% 206 16.5%
Unknown 68 — 158 — 327 — 553 —
Period of diagnosis
Diagnosed between April 2007 and November 2008 89 39.9% 68 15.5% 367 32.3% 524 29.1%
Diagnosed between December 2008 and July 2010 77 34.5% 146 33.2% 455 40.0% 678 37.7%
Diagnosed between August 2010 and March 2012 57 25.6% 226 51.4% 315 27.7% 598 33.2%
Deprivation (in deciles)
0–2, most deprived 30% 73 42.9% 153 42.4% 361 40.7% 587 41.4%
3–5 56 32.9% 101 28.0% 274 30.9% 431 30.4%
6–9, least deprived 40% 41 24.1% 107 29.6% 252 28.4% 400 28.2%
Unknown 53 79 250 382
Screening history
Never 97 43.5% 38 8.6% 86 7.6% 221 12.3%
Interval 7 3.1% 13 3.0% 101 8.9% 121 6.7%
Screen detected
Prevalent (on first test) 72 32.3% 290 65.9% 277 24.4% 639 35.5%
Incident (2.75–3.5 years after negative) 10 4.5% 5 1.1% 163 14.3% 178 9.9%
Lapsed (43.5 years after negative) 6 2.7% 30 6.8% 199 17.5% 235 13.1%
Post abnormal
Time from abnormal to diagnosis o1 year 18 8.1% 55 12.5% 152 13.4% 225 12.5%
Time from abnormal to diagnosis X1 year 13 5.8% 9 2.0% 159 14.0% 181 10.1%
Total N 223 100% 440 100% 1137 100% 1800 100%
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between the age groups (P¼ 0.434), but overall women in this
study were more deprived when compared with the national
distribution.
Overall, 29% (524) of cancers were diagnosed between April
2007 and November 2008, 38% (678) between December 2008 and
July 2010 and the remaining 33% (598) were diagnosed from
August 2010 to March 2012. The increase in cancers diagnosed in
the middle period is probably because of a large number of women
attending screening as a result of the much publicised death from
cervical cancer of celebrity Jade Goody in March 2009. The
increase in cervical cancer in England in 2009, particularly in
women aged 25–39 years, has been noted before (Sasieni and
Castanon, 2012).
The age distribution at which women are diagnosed with
cervical cancer has changed considerably during the study period.
Although the proportion diagnosed at age 20–24 years is currently
close to half of what it was at the start of the study (17% in the first
period vs 10% in the last period), the proportion diagnosed at age
25 years has increased almost three-fold (from 13% to 38%). In the
first period, most women aged 20–29 years were first invited for
screening at age 20 years and the number and rate of cervical
cancers increased with increasing age (Figure 1A). The age at
diagnosis begins to change in the period between December 2008
and July 2010, and there is a noticeable increase in the number and
rate of cancers among those aged 25–29 years (Figure 1B). From
August 2010 onwards (Figure 1C), when almost all women
diagnosed under age 26 years would not have been invited for
screening until age 25 years, we see a substantial increase in
diagnoses at age 25 years (despite the potential for undercounting
because of delays in registration) with a fall in numbers of cancers
diagnosed at age 26–29 years. In fact, the rate at age 25 years
increases to 41.5 per 100 000 (the highest observed during the
study period), and between 25.0 and 25.25 the rate peaks at 64.6
per 100 000 woman-years. It is also seen that the fall in diagnosed
women aged 26–29 years looks to be real in that there is a fall in
the rates even after adjusting for the effect of delayed registration.
An increase is also observed in women diagnosed between age
24.75 and 25 years because of women who attended and were
diagnosed promptly after their first invitation for screening, which
is sent out up to 6 months before their 25th birthday. It is not yet
possible to observe the effect of changing the age of first invitation
on women diagnosed at age 26–29 years because over 75% were
invited for screening at age 20 years.
The effect of the change in screening policy can be seen in the
differences in screening history between the age groups (Table 1).
Almost half of women diagnosed at age 20–24 years had never
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Figure 1. Rate and number of cancers in the study by age at diagnosis. (A) For those diagnosed between April 2007 and November 2008, (B) for
those diagnosed between December 2008 and July 2010, (C) for those diagnosed between August 2010 and March 2012. The darker shading
indicates cancers diagnosed at age 25.
Table 2. International Federation of Gynaecology and Obstetrics (FIGO) stage by age and date of diagnosis
1A 1Bþ Unknown Total
Age at diagnosis, years Period of diagnosis N % N % N % N %
20–24 Apr 2007–Nov 2008 37 42% 42 47% 10 11% 89 100%
Dec 2008–Jul 2010 26 34% 43 56% 8 10% 77 100%
Aug 2010–Mar 2012 14 25% 34 60% 9 16% 57 100%
25 Apr 2007–Nov 2008 41 60% 19 28% 8 12% 68 100%
Dec 2008–Jul 2010 94 64% 40 27% 12 8% 146 100%
Aug 2010–Mar 2012 158 70% 52 23% 16 7% 226 100%
26–29 Apr 2007–Nov 2008 194 53% 141 38% 32 9% 367 100%
Dec 2008–Jul 2010 255 56% 178 39% 22 5% 455 100%
Aug 2010–Mar 2012 176 56% 119 38% 20 6% 315 100%
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been screened (44%) compared with 9% of those aged 25 years and
8% of those aged 26–29 years. Women aged 25 years at diagnosis
were most likely to have been screen detected on their first test
(66%).
The distribution of FIGO stage at diagnosis in each period is
reported in Table 2. An increase in the proportion of stage 1B or
worse cancers diagnosed at age 20–24 years is seen between the
first study period and the last, whereas a decrease in stage 1Bþ
cancers is observed in women aged 25 years and no change in the
stage distribution is observed for women aged 26–29 years.
Changes in the screening histories over the study period are related
to the observed changes in the FIGO stage at diagnosis in these
young women.
Screening histories by FIGO stage are presented in Table 3.
Women who were not screened before diagnosis and those with
interval cancers were far more likely to be diagnosed with
advanced-stage cancer: 30% of 280 cancers (with known stage)
in this group were stage 2 or worse compared with 3% of 1335 that
were in some sense screen detected (i.e., all the other groups). The
unscreened and interval cases were also far less likely to have stage
1A cancer (20% of 280 cancers were known to be stage 1A) than
the other cases (70% of 1335 cancers).
DISCUSSION
The number of cancers diagnosed at age 25 years has changed
dramatically over the past few years; rates have increased three-fold
since the start of the study period. Cervical cancer is rare in women
aged 20–24 years when compared with women aged 25–29 years.
Results are distorted by the large proportion of women who are
screened and diagnosed at age 25 years: more cancers are
diagnosed at age 26 (n¼ 257) than at ages 20–24 years combined
(n¼ 223). Nevertheless, cancers in women aged 20–24 years tend
to be more advanced at diagnosis and of rarer histological types
than cancers in older women, leading to more aggressive
treatment. Indeed, more women had chemoradiotherapy for
cancer diagnosed at age 20–24 years (n¼ 58) than at age 25 years
(n¼ 29). Screen-detected cancers are most likely to be diagnosed as
microinvasive cancer (stage 1A), whereas those who were never
screened or had interval cancers are most likely to be diagnosed
with stage 2 or worse cervical cancer.
This is the largest study of women diagnosed with cervical
cancer under the age of 30 years. It includes over 90% of all cancers
at age 20–29 years in England and has complete screening
histories. However, it will not be possible to study the full impact of
the change in policy on rates of cervical cancer until the first cohort
of women invited for screening at age 25 years reach the age of 30
years (around 2015). We cannot disentangle changes in underlying
risk factors from changes in the screening policy, both of which are
confounded by the Jade Goody effect. Nevertheless, by dividing the
study period in three we have been able to show the impact of the
change in policy on the age at which cancer is diagnosed.
A weakness of this study is that delays in reporting newly
diagnosed cases to the audit mean that the numbers in the most
recent period will be underreported. We have taken the view that
the timeliness of the data justifies publication even though it is
likely to be incomplete. Certainly, the increase in cancers diagnosed
at age 25 years (despite the likelihood of underreporting) seems to
justify such a decision. We have attempted to adjust the rates
taking into account the historical impact of delayed registration.
There are three possible explanations for the increase in cancers
observed at age 25 years: (1) cancers are being diagnosed later, that
is, cancers that would have been screen detected at age 20–24 years
are now diagnosed as stage 1A cancers at age 25 years; (2) cancers
are not being prevented, that is, women who would have been
treated for CIN2/3 at age 20–24 years are now being diagnosed
with cancer at age 25 years; (3) cancers are being diagnosed earlier,
that is, women who would have been diagnosed with cancer at age
26 or 27 years on their third round of screening are now being
diagnosed at age 25 years on their first screening test. It is not
possible to say which of these scenarios has played the most
prominent role, but our results show no evidence of an increase in
1B or worse cervical cancer at age 25 years. Whatever the
underlying reasons for the observed changes, results show that 62%
of cancer in women aged 20–29 years were diagnosed as stage 1A
cancer and of these 94% (of those with known treatment) were
treated with Large loop excision of the transformation zone
(LLETZ) or Cone biopsy only. These cases should be considered
successes of the programme because they not only have excellent
survival (98% 5-year survival; Kosary, 2007) but also the treatment
is essentially the same as would be recommended for women with
high-grade cervical intraepithelial neoplasia.
We are unable to distinguish cytology tests taken in response to
symptoms from those following an invitation for screening.
Table 3. Screening history (at least 14 days before diagnosis) by the International Federation of Gynaecology and Obstetrics (FIGO) stage among those
with known stage
Stage 1A Stage 1B Stage 2þ Cases with known stage Cases with stage unknown
Never 35 20% 83 48% 55 32% 173 100% 48/221 21%
Interval 22 21% 56 52% 29 27% 107 100% 14/121 12%
Subtotal 57 20% 139 50% 84 30% 280 100% 62/342 18%
Screen detected
Prevalent (on first test) 422 72% 150 25% 18 3% 590 100% 49/639 8%
Incident (2.75–3.5 years after negative) 121 72% 42 25% 4 2% 167 100% 11/178 6%
Lapsed (43.5 years after negative) 155 71% 58 27% 5 2% 218 100% 17/235 7%
Subtotal 698 72% 250 26% 27 3% 975 100% 77/1052 7%
Post abnormal
Time from abnormal to diagnosis o1 year 145 70% 57 27% 6 3% 208 100% 17/225 8%
Time from abnormal to diagnosis X1 year 95 63% 44 29% 13 9% 152 100% 29/181 8%
Sub-total 240 67% 101 28% 19 5% 360 100% 46/406 11%
Total 995 62% 490 30% 130 8% 1615 100% 185/1800 10%
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However, the large proportion of advanced stage cancers among
women never screened and interval cancers suggest that our
screening classification successfully identified those who are most
likely to have had symptoms. Nevertheless, women who had
cytology taken in response to symptoms may have been included
in any of the other categories if the sample was taken more than 14
days before diagnosis.
Studies of cervical cancer in women aged 20–29 in the United
Kingdom are few and tend to be small (Rieck et al, 2006; Nair et al,
2007; Herbert et al, 2008; Patel et al, 2012). The combined results
for all but the largest study include a total of just 18 cancers (all of
which were in women offered screening from age 20 years)
diagnosed at age 20–24 years. Over 60% of cancers in these studies
were stage 1A and roughly the same proportions were found to be
screen detected. The largest study by Patel et al (2012) included
152 cases aged 20–29 years diagnosed over a 10-year period in the
north east (NE) of England. They found a much higher proportion
of cancers at age 20–24 years (26%) than found in this national
study (12%). In 2010, cancers diagnosed at age 20–24 years
accounted for just 2% of all cervical cancers diagnosed in England
(Office for National Statistics, 2012).
Patel et al (2012) compared incidence rates between 2000–2002
and 2007–2009 in NE England and concluded there has been an
increase in diagnoses of cancer in women under the age of 30 years.
However, results were similar for Wales where they continue to
screen from age 20 years. The authors concluded that rather than
the change in policy, high rates of sexually transmitted infections
(STIs) and other underlying risk factors affecting the population of
the NE of England are responsible for the increased rates of
cervical cancer. This, in addition to the fact that most women in
the study of Patel et al (2012) were invited for screening from age
20 years, may account for the differences (described above) in the
proportion of women diagnosed at age 20–24 years between
studies.
Similarly, Foley et al (2011) reported increasing rates of cervical
cancer in England in women under age 40 years, with those born
from 1972 onwards at greater risk. Incidence rates since 1975 show
rates in women aged 20–24 years ofB2.1 per 100 000 women from
1975 up until 1999. Between 2000 and 2004, the average rate
jumped to 3.0 and it has remained the same in the following 5-year
period. Rates in women aged 25–29 years are harder to interpret;
during the 1980s, the average rate was 11.3 per 100 000 women,
between 1990 and 2004 it was 9.6 per 100 000, and it then jumped
to 15.8 per 100 000 between 2005 and 2009 (Office for National
Statistics, 1975-2010). The increase of cervical cancer in women
born since 1972 is most likely because of an increase in the
underlying risk factors for cervical cancer (rates of STIs, smoking).
These trends are concerning, and efforts should be focussed on
increasing coverage among women aged 25–29 years rather than
on reintroducing screening among those aged 20–24 years. Longer-
term HPV vaccination should greatly reduce cervical cancer rates
in those born since 1994.
There was concern (Fiander, 2008) that inviting women at age
25 years would lead to a drop in coverage in those under age 30
years. Latest statistics show that 3-yearly coverage in those aged
25–29 years has remained roughly the same (B62%) from 2002 to
2012 (screening programme stats 2011/12). Nevertheless, it is low
compared with coverage among those aged 30–49 years (71% on
average).
Results presented here show that most cancers diagnosed at age
20–29 years are screen detected microinvasive cancer (stage 1A)
with excellent prognosis. As a result of the change in policy, there
has been a shift in the age at which women are diagnosed; since
August 2010, half of all cancers in this age group have been
diagnosed at age 25 years. Although cancer at age 20–24 years
tends to be diagnosed at more advanced stages, it is rare in this age
group.
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APPENDIX 1
Table A1. Screening history classification
No early recall Early recall¼ gap o1 year Early Recall¼ gap X1 year
Time from last suspend to diagnosis None
p4
Months
44
Months None
p4
Months
44
Months None
p4
Months 44 Months
None N¼ 212 N¼ 614 N¼ 127 N¼ 3 N¼ 25 N¼ 16 N¼ 9 N¼ 46 N¼ 31
Never Screen
detected
(SD) on
first test
Post
abnormal
Post
abnormal
SD on
first test
Post
abnormal
Post
abnormal
Post
abnormal
Post
abnormal
Time from last routine
test to early recall,
suspend or diagnosis,
whichever comes first
43.5
years
N¼ 23 N¼ 223 N¼ 49 N¼ 0 N¼ 23 N¼ 7 N¼ 3 N¼ 7 N¼ 6
Lapsed SD lapsed Post
abnormal
Lapsed SD lapsed Post
abnormal
Post
abnormal
Post
abnormal
Post
abnormal
2.75–3.5
years
N¼ 24 N¼ 176 N¼ 29 N¼ 2 N¼ 14 N¼ 8 N¼ 2 N¼ 5 N¼ 7
Interval SD
incidence
Post
abnormal
Interval SD
incidence
Post
abnormal
Post
abnormal
Post
abnormal
Post
abnormal
o2.75
years
N¼ 64 N¼ 27 N¼ 2 N¼ 0 N¼ 1 N¼ 0 N¼ 0 N¼ 0 N¼ 0
Interval Interval Interval Interval Interval Interval Interval Interval Interval
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